Ibrexafungerp shows ‘encouraging’ results in recurrent vulvovaginal candidiasis treatment

Oral ibrexafungerp had positive outcomes in patients with recurrent vulvovaginal candidiasis who had failed fluconazole treatment, according to a press release from Scynexis.

Data from the phase 3 CANDLE nested sub-study — which were presented at the International Society for the Study of Vulvovaginal Diseases XXVI World Congress and International Vulvovaginal Disease Update — showed 71% of the 24 patients enrolled achieved a substantial reduction or total elimination of signs and symptoms after 1 day of treatment with ibrexafungerp (Brexafemme). Ibrexafungerp was administered in 300 mg doses for 3 days twice daily.

Within the subgroup, 10 patients also had microbiological failure or persistent positive cultures after fluconazole treatment. Of these, eight reported favorable clinical response after 1 day of ibrexafungerp, further confirming the positive trend.

“The response to ibrexafungerp in this clinically challenging population is extremely encouraging and further demonstrates the potential efficacy of ibrexafungerp to treat recurrent yeast infections in patients with limited treatment options,” Nkechi Azie, MD, MBA, vice president of clinical development and medical affairs at Scynexis, said in the release. “We hope to expand upon these data with the recently announced phase 3b VANQUISH study.”

Scynexis plans to present the main results of this study at the upcoming Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting.